中央の物質P受容体のブロックによって抗うつ剤の活性に対する明確なメカニズム
M S Kramer1, N Cutler, J Feighner
1Merck Research Laboratories, West Point, PA 19456, USA. Mark_Kramer@merck.com
まとめ
物質Pのアンタゴニストは,新しい抗うつ剤として有望であることが示されています. MK-869は臨床試験で有意な抗うつ効果を示し,物質Pを示唆した.
科学分野:
- 神経科学は神経科学である.
- 精神科医は精神病を患っている.
- 薬理学 薬理学とは
背景:
- 物質Pは,ストレスを調節する脳の領域に存在します.
- モノアミネルジック系は,これらの領域に収束する.
- これは,物質Pアンタゴニストが心理療法的な効果を持つ可能性があることを示唆している.
研究 の 目的:
- 物質Pアンタゴニストの心理療法の可能性を調査する.
- 人間における物質PアンタゴニストMK-869の抗うつ効果を評価する.
主な方法:
- 豚実験における臨床前研究 (孤立による発声).
- 重度のうつ病患者のプラセボ対照臨床試験である.
主要な成果:
- 物質Pアンタゴニストは,既存の抗うつ剤と似て,豚の発声を抑えた.
- MK-869は,ヒトでの試験で強力な抗うつ剤効果を示しました.
- 伝統的な抗うつ剤とは異なり,物質Pアンタゴニストはモノアミン系と相互作用しませんでした.
結論:
- サブスタンスPアンタゴニストは,精神疾患に対する新たな治療の道を示しています.
- 物質Pは,精神疾患の病理生理学において重要な役割を果たしています.
- MK-869の有効性は,抗うつ剤の作用の新しいメカニズムを示唆しています.
関連する概念動画
G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...


